MPE has received funding from the following sources in 2021 and 2022:
Industry supporters
- AbbVie
- Amgen
- Alexion
- BeiGene
- Binding Site
- Bristol Myers Squibb
- GlaxoSmithKline
- Janssen
- Novartis
- Oncopeptides
- Pfizer
- Regeneron
- Roche
- Sanofi
- Menarini Stemline
- Takeda
- Sebia
- Prothena
- SkylineDx
- Sandoz
Public supporters
Horizon Europe
Innovative Medicine Initiative (IMI)
- Horizon 2020 CARAMBA
![EU funded by European Union logo](https://www.mpeurope.org/wp-content/uploads/2023/04/EN-Funded-by-the-EU-PANTONE-1024x215.png)
- Horizon Europe ASCERTAIN
![EU funded by European Union logo](https://www.mpeurope.org/wp-content/uploads/2023/04/EN-Funded-by-the-EU-PANTONE-1024x215.png)
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754658.
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101094938.
- IMI HARMONY
- SISAQOL IMI
You can freely download the funding sources reports by clicking on the links below: